Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites
Status:
Completed
Trial end date:
2019-08-23
Target enrollment:
Participant gender:
Summary
This is an open label, single sequence, crossover study. In Part 1, eligible subjects will
participate in 3 treatment periods, in which they will receive the following treatments in
turn: 1) In Period 1, a single 350-mg dose of relacorilant administered alone, 2) In Period
2, once daily 200-mg doses of itraconazole administered for 3 days; 3) In Period 3, single
350-mg dose of relacorilant administered with a concomitant 200-mg dose of itraconazole and
continued once daily 200-mg doses of itraconazole for three additional days.
If Part 2 is conducted, eligible subjects will participate in 2 treatment periods, in which
they will receive the following treatments in turn: 1) In Period A, once daily 300-mg doses
of relacorilant alone for 10 days; 2) In Period B, once daily 300-mg doses of relacorilant in
combination with once daily 200-mg doses of itraconazole for 10 days.